In the past week, TNGX stock has gone down by -8.82%, with a monthly decline of -28.19% and a quarterly plunge of -65.84%. The volatility ratio for the week is 7.66%, and the volatility levels for the last 30 days are 13.68% for Tango Therapeutics Inc. The simple moving average for the past 20 days is 1.36% for TNGX’s stock, with a -53.47% simple moving average for the past 200 days.
Is It Worth Investing in Tango Therapeutics Inc (NASDAQ: TNGX) Right Now?
The 36-month beta value for TNGX is also noteworthy at 0.75. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TNGX is 49.37M, and at present, short sellers hold a 14.40% of that float. The average trading volume of TNGX on December 05, 2024 was 1.89M shares.
TNGX) stock’s latest price update
Tango Therapeutics Inc (NASDAQ: TNGX)’s stock price has gone rise by 5.68 in comparison to its previous close of 3.52, however, the company has experienced a -8.82% decrease in its stock price over the last five trading days. businesswire.com reported 2024-12-03 that BOSTON–(BUSINESS WIRE)–Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics’ Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics’ 2023 Inducement.
Analysts’ Opinion of TNGX
Many brokerage firms have already submitted their reports for TNGX stocks, with Jefferies repeating the rating for TNGX by listing it as a “Buy.” The predicted price for TNGX in the upcoming period, according to Jefferies is $19 based on the research report published on July 17, 2024 of the current year 2024.
Piper Sandler gave a rating of “Overweight” to TNGX, setting the target price at $18 in the report published on February 12th of the current year.
TNGX Trading at -30.50% from the 50-Day Moving Average
After a stumble in the market that brought TNGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.40% of loss for the given period.
Volatility was left at 13.68%, however, over the last 30 days, the volatility rate increased by 7.66%, as shares surge +11.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.35% lower at present.
During the last 5 trading sessions, TNGX fell by -11.40%, which changed the moving average for the period of 200-days by -67.31% in comparison to the 20-day moving average, which settled at $3.66. In addition, Tango Therapeutics Inc saw -62.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNGX starting from Rothenberg Mace, who purchase 10,000 shares at the price of $3.78 back on Nov 18 ’24. After this action, Rothenberg Mace now owns 31,250 shares of Tango Therapeutics Inc, valued at $37,800 using the latest closing price.
Rothenberg Mace, the Director of Tango Therapeutics Inc, purchase 10,000 shares at $3.62 during a trade that took place back on Nov 14 ’24, which means that Rothenberg Mace is holding 21,250 shares at $36,200 based on the most recent closing price.
Stock Fundamentals for TNGX
Current profitability levels for the company are sitting at:
- -3.22 for the present operating margin
- 0.96 for the gross margin
The net margin for Tango Therapeutics Inc stands at -2.84. The total capital return value is set at -0.44. Equity return is now at value -48.80, with -31.62 for asset returns.
Currently, EBITDA for the company is -111.76 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 8.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.00.
Conclusion
In summary, Tango Therapeutics Inc (TNGX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
